To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control. In addition, the tolerability and safety of SR58611A in patients with MDD will be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
680
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States
Change from baseline in total score of a depression rating scale at 8 weeks
Safety assessments
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.